Passage Bio
PASG
66 hedge funds and large institutions have $51.5M invested in Passage Bio in 2022 Q4 according to their latest regulatory filings, with 7 funds opening new positions, 15 increasing their positions, 24 reducing their positions, and 15 closing their positions.
5% more capital invested
Capital invested by funds: $49.3M → $51.5M (+$2.29M)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
0.19% less ownership
Funds ownership: 3.62% → 3.42% (-0.19%)
12% less funds holding
Funds holding: 75 → 66 (-9)
38% less repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 24
53% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 15
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LCM
Lynx1 Capital Management
San Juan,
Puerto Rico
|
+$761K |
| 2 |
NM
Newtyn Management
New York
|
+$618K |
| 3 |
EAM
Erste Asset Management
Vienna,
Austria
|
+$492K |
| 4 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$412K |
| 5 |
B
Bailard
Foster City,
California
|
+$198K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
-$1.8M |
| 2 |
Morgan Stanley
New York
|
-$587K |
| 3 |
WP
Woodline Partners
San Francisco,
California
|
-$530K |
| 4 |
BlackRock
New York
|
-$278K |
| 5 |
Marshall Wace
London,
United Kingdom
|
-$242K |
PASG Hedge Fund Activity: Q4 2022 in Review
66 of the 6,237 institutional investors tracked by Wall St. Rank reported a position in Passage Bio (PASG) for Q4 2022, worth a combined $51.5M — up 4.7% from $49.3M a quarter earlier.
Sellers outnumbered buyers: 15 funds closed out of PASG and 7 opened new positions — a net loss of 8 holders — while 24 trimmed existing stakes and 15 added.
The largest buyer was Lynx1 Capital Management, adding an estimated $761K. The largest seller was Deep Track Capital, exiting entirely with an estimated $1.8M sold.
- 66 institutional investors held Passage Bio (PASG) as of Q4 2022, down from 75 in Q3 2022.
- Funds reported $51.5M of Passage Bio stock for Q4 2022, up 4.7% quarter-over-quarter.
- 7 funds opened new Passage Bio positions in Q4 2022 and 15 closed out, a net change of -8 holders.
- The largest Passage Bio buyer in Q4 2022 was Lynx1 Capital Management, an estimated $761K added.
- The largest Passage Bio seller in Q4 2022 was Deep Track Capital, an estimated $1.8M sold.
Based on aggregated 13F filings for Q4 2022.